Summary & Overview
HCPCS J1885: Injection, Ketorolac Tromethamine, per 15 mg
HCPCS Level II code J1885 denotes the injectable formulation of ketorolac tromethamine billed per 15 mg unit. Ketorolac is an NSAID commonly used for short-term management of moderate to severe pain in settings where parenteral therapy is required, including emergency departments, outpatient clinics, and ambulatory surgery centers. Nationally, billing for injectable analgesics like ketorolac is significant because of its role as an opioid-sparing agent and its frequent use in acute care.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmark information on utilization and unit-based billing for J1885, common clinical contexts for administration, and payer policy considerations that affect coverage and coding. The publication also summarizes typical sites of service, common billing modifiers when applicable, and practical coding notes relevant to claims submission.
This summary is intended for coders, billing managers, and policy analysts seeking a concise reference on HCPCS Level II code J1885, its clinical application, and the payer landscape that governs reimbursement and claim processing at a national level.
Billing Code Overview
HCPCS Level II code J1885 represents injection of ketorolac tromethamine, per 15 mg. This medication is a nonsteroidal anti-inflammatory drug (NSAID) used for short-term management of moderate to severe pain, often when opioid-sparing therapy is appropriate.
-
Service type: Drug administration (injectable analgesic)
-
Typical site of service: Outpatient clinics, emergency departments, ambulatory surgery centers, and other facility settings where parenteral analgesics are administered.
Clinical & Coding Specifications
Clinical Context
A 45-year-old patient presents to an urgent care clinic with acute moderate-to-severe musculoskeletal pain after a fall during weekend recreational activity. The patient reports pain localized to the right shoulder with limited range of motion and tenderness on palpation. After triage and brief evaluation by the clinician, nonsteroidal anti-inflammatory therapy is indicated for short-term pain control. The clinician determines that an intramuscular injection is appropriate because the patient requires rapid analgesia, oral intake is limited, or prior oral NSAIDs were ineffective or contraindicated.
The clinical workflow: patient registration and allergy/medication reconciliation; focused history and physical exam documenting location, severity, onset, and functional impact of pain; assessment of contraindications to ketorolac (active bleeding, renal impairment, NSAID allergy, recent anticoagulant use, pregnancy); informed consent for injection; preparation of J1885 (ketorolac tromethamine) dose per 15 mg unit; administration via intramuscular or intravenous route as clinically indicated; monitoring for immediate adverse effects (bleeding, hypotension, allergic reaction); documentation of drug name, dose, route, lot number, site, patient response, and any counseling. Typical site of service: outpatient clinics, urgent care centers, emergency departments, and ambulatory surgical centers for short-term analgesia. Service type: pharmaceutical injectable non-chemotherapeutic, short-term analgesic (single-dose or short course injectable NSAID).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|